Poster — Thur Eve — 53: Analysis of the distribution of dose delivery during respiratory‐gated step‐and‐shoot IMRT for lung cancer radiotherapy

• Published in: Medical physics (Lancaster) 2012-07, Vol.39 (7), p.4634-4635
• Main Authors: Xhaferllari, I, El‐Sherif, O, Gaede, S
• Format: Article
• Language: English
• Subjects: Cancer; Dosimetry; Drug delivery; Error analysis; Intensity modulated radiation therapy; Lungs; Medical treatment planning; Multileaf collimators; Radiation therapy; Radiotherapy sources
• ISSN: 0094-2405; 2473-4209
• DOI: 10.1118/1.4740161

Respiratory motion is a large source of dosimetric error when treating lung cancer with Intensity Modulated Radiation Therapy (IMRT). The asynchronicity of the tumour motion and the multileaf collimator (MLC) used to modulate the radiation beam intensity, leads to the interplay effect. One method to account for this effect is respiratory gating. Treatment planning optimization for gated IMRT is performed on a subset average 4D‐CT which includes the phases surrounding end exhalation. However, this assumes that the beam delivery will be evenly distributed amongst those phases. This study investigates the distribution of beam delivery during gated step‐and‐shoot IMRT (SS‐IMRT) for both early and late stage non‐small cell lung cancer (NSCLC). Four Stage I NSCLC patients, prescribed a dose of 54 Gy in 3 fractions, and five Stage III NSCLC patients, prescribed a dose of 60 Gy in 30 fractions, were retrospectively planned with high and low modulation beams‐IMRT, and delivered using the QUASAR™ Programmable Respiratory Motion Platform with 15 mm and 20 mm peak‐to‐peak sinusoidal motion and real patient breathing motion. The percent monitor units delivered at each phase were compared. For Stage I patients, the monitor units delivered were evenly distributed over the gating window due to a high number of monitor units delivered per control point. For Stage III patients, as the complexity of SS‐IMRT increases, there were more monitor units delivered in the initial gating phase. This dose discrepancy could potentially lead to geographic miss of the tumour and should be taken into account during treatment planning.